Skip to content

Brain research in Whiplash Associated Disorder

Brain research in Whiplash Associated Disorder - BRIWAD

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON35947
Enrollment
32
Registered
2011-07-08
Start date
2012-01-18
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

whiplash

Interventions

None listed

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Females, between 18 and 45 years. Right-handed Body Mass Index equal/less than 29 For patients: Rear end automobile collision Whiplash Associated Disorder (WAD) classified as grade I or II At least 2 years from the accident, up to 10 years. No treatment for WAD other than painkillers

Exclusion criteria

Exclusion criteria: Pregnant or in menopause. Use of anticoagulants, medication that affect the immune system or investigation drug. Current or recent alcohol or substance abuse. Current or recent infectious, inflammatory, metabolic or systemic disease. Impossibility to perform a PET scan (claustrophobia...) Diagnosis of Depression or Anxiety.

Design outcomes

Primary

MeasureTime frame
The primary objective is to compare regional cerebral blood flow (rCBF) in response to non-painful neck stimulus, between patients with WAD and healthy matched control volunteers, ascertained by Positron Emission Tomography (PET) scan. Each subject will be exposed to four different conditions: rest state, placebo-like stimuli, low intensity stimuli, and high intensity neck stimuli. The rCBF corresponding to exposure to each stimulus is measured in the brain by PET.

Secondary

MeasureTime frame
The secondary objective is to determine if there is a correlation between rCBF response and the results in the questionnaires.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)